CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Total revenues	$ 0	$ 690
Costs and Expenses:
Costs of goods sold	0	70
Research and development	38,239	17,342
Sales and marketing	5,799	226
General and administrative	13,131	4,650
Total costs and expenses	57,169	22,288
Operating loss	(57,169)	(21,598)
Changes in fair market value of warrant liabilities	1,218	(86,378)
Loss on induced exchanges of debt	0	(13,005)
Interest expense	(10,142)	(2,647)
Interest and other income	1,694	416
Insurance reimbursement	190	4,366
Foreign currency transaction gain, net	0	84
Loss before income tax	(64,209)	(118,762)
Income tax (expense) benefit	0	0
Net loss	(64,209)	(118,762)
Net loss attributable to noncontrolling interest	(40)	(17)
Net loss attributable to Immunomedics, Inc. stockholders	$ (64,169)	$ (118,745)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in usd per share)	$ (0.34)	$ (0.97)
Weighted average shares used to calculated loss per common share (basic and diluted) (in shares)	186,937	122,550
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	$ 4	$ (73)
Unrealized gain on securities available for sale	15	32
Other comprehensive income (loss), net of tax:	19	(41)
Comprehensive loss	(64,190)	(118,803)
Comprehensive loss attributable to noncontrolling interest	(40)	(17)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	(64,150)	(118,786)
Product sales
Total revenues	0	526
License fee and other revenues
Total revenues	0	1
Research and development
Total revenues	$ 0	$ 163